RxSight Q4 revenue falls 19% on lower LDD sales

Reuters02-26

RxSight Q4 revenue falls 19% on lower LDD sales

Overview

Ophthalmic device firm's Q4 revenue fell 19% yr/y on lower LDD sales
Q4 gross profit margin improved, driven by favorable product mix
Company reported deeper Q4 net loss

Outlook

RxSight projects 2026 revenue between $120.0 mln and $135.0 mln
Company expects 2026 gross margin of 70% to 72%
RxSight forecasts 2026 operating expenses of $150.0 mln to $160.0 mln

Result Drivers

LAL SALES GROWTH - LAL unit sales increased 12% to 109,615, contributing to revenue despite overall decline
PRODUCT MIX SHIFT - Gross profit margin improved to 76.6% from 70.7% due to higher percentage of revenue from LAL sales
LDD SALES DECLINE - LDD revenue decreased 72% in Q4, contributing to overall revenue decline

Company press release: ID:nGNX3B3JHD

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Gross Profit		$25.30 mln
Q4 Operating Expenses		$36.60 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Rxsight Inc is $10.00, about 11.9% above its February 24 closing price of $8.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614051054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614051054","market":"nz","top_or_hot":-1,"title":"RxSight Q4 revenue falls 19% on lower LDD sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>RxSight Q4 revenue falls 19% on lower LDD sales</title></head><body><p><span>Overview</span></p><ul><li><p>Ophthalmic device firm's Q4 revenue fell 19% yr/y on lower LDD sales</p></li><li><p>Q4 gross profit margin improved, driven by favorable product mix</p></li><li><p>Company reported deeper Q4 net loss</p></li></ul><p><span>Outlook</span></p><ul><li><p>RxSight projects 2026 revenue between $120.0 mln and $135.0 mln</p></li><li><p>Company expects 2026 gross margin of 70% to 72%</p></li><li><p>RxSight forecasts 2026 operating expenses of $150.0 mln to $160.0 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LAL SALES GROWTH - LAL unit sales increased 12% to 109,615, contributing to revenue despite overall decline</p></li><li><p>PRODUCT MIX SHIFT - Gross profit margin improved to 76.6% from 70.7% due to higher percentage of revenue from LAL sales</p></li><li><p>LDD SALES DECLINE - LDD revenue decreased 72% in Q4, contributing to overall revenue decline</p></li></ul><p>Company press release: <span>ID:nGNX3B3JHD</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$25.30 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$36.60 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 8 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Rxsight Inc is $10.00, about 11.9% above its February 24 closing price of $8.94</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight Q4 revenue falls 19% on lower LDD sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight Q4 revenue falls 19% on lower LDD sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 05:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>RxSight Q4 revenue falls 19% on lower LDD sales</title></head><body><p><span>Overview</span></p><ul><li><p>Ophthalmic device firm's Q4 revenue fell 19% yr/y on lower LDD sales</p></li><li><p>Q4 gross profit margin improved, driven by favorable product mix</p></li><li><p>Company reported deeper Q4 net loss</p></li></ul><p><span>Outlook</span></p><ul><li><p>RxSight projects 2026 revenue between $120.0 mln and $135.0 mln</p></li><li><p>Company expects 2026 gross margin of 70% to 72%</p></li><li><p>RxSight forecasts 2026 operating expenses of $150.0 mln to $160.0 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LAL SALES GROWTH - LAL unit sales increased 12% to 109,615, contributing to revenue despite overall decline</p></li><li><p>PRODUCT MIX SHIFT - Gross profit margin improved to 76.6% from 70.7% due to higher percentage of revenue from LAL sales</p></li><li><p>LDD SALES DECLINE - LDD revenue decreased 72% in Q4, contributing to overall revenue decline</p></li></ul><p>Company press release: <span>ID:nGNX3B3JHD</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$25.30 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$36.60 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 8 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Rxsight Inc is $10.00, about 11.9% above its February 24 closing price of $8.94</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXST","symbol_name":"RxSIGHT, INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL1N3ZL1AZ:1","article_id":"2614051054","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614051054","pubTimestamp":1772055873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RxSight Q4 revenue falls 19% on lower LDD salesOverviewOphthalmic device firm's Q4 revenue fell 19% yr/y on lower LDD salesQ4 gross profit margin improved, driven by favorable product mixCompany repor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXST":"RxSIGHT, INC.","BK4198":"医疗保健用品","BK4539":"次新股"},"translate_title":"由于LDD销售额下降，RxSight第四季度收入下降19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXST":0.9},"content_text":"RxSight Q4 revenue falls 19% on lower LDD salesOverviewOphthalmic device firm's Q4 revenue fell 19% yr/y on lower LDD salesQ4 gross profit margin improved, driven by favorable product mixCompany reported deeper Q4 net lossOutlookRxSight projects 2026 revenue between $120.0 mln and $135.0 mlnCompany expects 2026 gross margin of 70% to 72%RxSight forecasts 2026 operating expenses of $150.0 mln to $160.0 mlnResult DriversLAL SALES GROWTH - LAL unit sales increased 12% to 109,615, contributing to revenue despite overall declinePRODUCT MIX SHIFT - Gross profit margin improved to 76.6% from 70.7% due to higher percentage of revenue from LAL salesLDD SALES DECLINE - LDD revenue decreased 72% in Q4, contributing to overall revenue declineCompany press release: ID:nGNX3B3JHDKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Gross Profit$25.30 mlnQ4 Operating Expenses$36.60 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 8 \"hold\" and 2 \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy.\"Wall Street's median 12-month price target for Rxsight Inc is $10.00, about 11.9% above its February 24 closing price of $8.94For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614051054","isCrawlerRequest":true}